1. Home
  2. NVCR vs SCL Comparison

NVCR vs SCL Comparison

Compare NVCR & SCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • SCL
  • Stock Information
  • Founded
  • NVCR 2000
  • SCL 1932
  • Country
  • NVCR Switzerland
  • SCL United States
  • Employees
  • NVCR N/A
  • SCL N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • SCL Package Goods/Cosmetics
  • Sector
  • NVCR Health Care
  • SCL Consumer Discretionary
  • Exchange
  • NVCR Nasdaq
  • SCL Nasdaq
  • Market Cap
  • NVCR 1.9B
  • SCL 1.2B
  • IPO Year
  • NVCR 2015
  • SCL N/A
  • Fundamental
  • Price
  • NVCR $17.71
  • SCL $59.25
  • Analyst Decision
  • NVCR Buy
  • SCL
  • Analyst Count
  • NVCR 6
  • SCL 0
  • Target Price
  • NVCR $32.83
  • SCL N/A
  • AVG Volume (30 Days)
  • NVCR 1.6M
  • SCL 93.2K
  • Earning Date
  • NVCR 07-24-2025
  • SCL 07-30-2025
  • Dividend Yield
  • NVCR N/A
  • SCL 2.60%
  • EPS Growth
  • NVCR N/A
  • SCL 47.62
  • EPS
  • NVCR N/A
  • SCL 2.45
  • Revenue
  • NVCR $621,711,000.00
  • SCL $2,222,111,000.00
  • Revenue This Year
  • NVCR $5.56
  • SCL $8.56
  • Revenue Next Year
  • NVCR $9.19
  • SCL $6.89
  • P/E Ratio
  • NVCR N/A
  • SCL $24.19
  • Revenue Growth
  • NVCR 18.27
  • SCL N/A
  • 52 Week Low
  • NVCR $14.17
  • SCL $44.23
  • 52 Week High
  • NVCR $34.13
  • SCL $94.77
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 51.32
  • SCL 66.35
  • Support Level
  • NVCR $17.53
  • SCL $54.28
  • Resistance Level
  • NVCR $18.70
  • SCL $56.24
  • Average True Range (ATR)
  • NVCR 0.72
  • SCL 1.46
  • MACD
  • NVCR 0.09
  • SCL 0.41
  • Stochastic Oscillator
  • NVCR 60.56
  • SCL 94.74

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About SCL Stepan Company

Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.

Share on Social Networks: